Its book value per share for the most recent quarter is $-0.01 while its price to book ratio for the same period is 0, as for as the company's cash per share for the most recent quarter is $0.1, however its price to cash per share ratio for the same period is 6.64. The Average Volume of the company is 798.29 Million, while the Volume of the company in the last trading session was 16 Billion. The relative volume of the stock is 20.56. The price/earnings to growth ratio (PEG ratio) is a stock's price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period. Many investors will use the CCI in conjunction with other indicators when evaluating a trade. The company has its outstanding shares of 36.34M.
Repros Therapeutics Inc. (RPRX) performance during the last one year degraded -75 percent, while its year to date (YTD) performance showed a negative trend of -59.85 percent. (RPRX) has been moved; whether it performed well or not. Previously Repros Therapeutics (NASDAQ:RPRX) reported $-0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.22 by $0.14 with surprise factor of 63.6%. R&D expenses dropped 54% to $3.2 million for the six-month period closed June 30, 2017, as against $7 million for the same semester in the prior year.
What Historical Figures Say About Repros Therapeutics Inc. The $0.4 level represents at least another 46.67% downside for the stock from its current price. Moving averages can be very helpful for identifying peaks and troughs. The company has Relative Strength Index (RSI 14) of 89.42 along with Average True Range (ATR 14) of 0.08.
Organizations that control large sums of money, like pension funds, insurance companies or mutual funds, who buy stocks are known as institutional investors. Next quarter's EPS is forecasted at $-0.32 with next year's EPS anticipated to be $-1.01. As its institutional ownership stands at 20.10%, the ownership flows provide evidence to be a good test of stock returns. A high ROE indicates successfully earning more assets and value for its shareholders off its reinvested earnings.
Looking forward, the company's quarterly earnings in the three months through September 2017 and in the quarter ending December 2017, reflecting -587747% and -624475% growth, respectively.
The company shows its Return on Assets (ROA) value of -212.1%. Moving out to look at the previous month volatility move, the stock is at 17.55%. Simply put, volatility is a reflection of the degree to which price moves. The company's distance from 52-week high price is -65.60% and current price is above +188.46% from 52-week low price. The RSI is computed base on the speed and direction of a stock's price movement. When investing in a volatile security, the risk of success is increased just as much as the risk of failure. The trading saw a strength at $2.15, the 52-week high. The current consensus recommendation provided by covering analysts is 2.00. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.